Publications by authors named "Deepali N Tapre"
Article Synopsis
- Empagliflozin, an SGLT2 inhibitor, was tested for its antidepressant effects in diabetic rats using a model that simulates neuroinflammation-mediated depression after performing olfactory bulbectomy (OBX) surgery.
- The study involved treating the rats with oral doses of empagliflozin, metformin, and clomipramine over 14 days, and measuring changes in behavior and antioxidant levels.
- Results indicated that empagliflozin improved depressive behaviors and restored antioxidant levels in the brain, suggesting it may help treat depression linked to neuroinflammation and oxidative stress.
Background: Alzheimer's disease (AD) is one of the most challenging and prevalent neurodegenerative disorder globally with a rising prevalence, characterized by progressive cognitive decline, memory loss, and behavioural changes. Current research aims to determine the nootropic and anti-amnesic effect of Empagliflozin (EMPA) against scopolamine-induced amnesia in rats, by modulating the cholinergic and N-Methyl D-Aspartate (NMDA) receptors.
Methods: Rats were treated once daily with an EMPA (5 and 10 mg/kg) and donepezil (2.